Performance evaluation of a laboratory developed PCR test for quantitation of HIV-2 viral RNA
暂无分享,去创建一个
Y. Liu | S. Peel | L. Jagodzinski | M. Manak | H. Hack
[1] R. Gangakhedkar,et al. Partial pol Sequences from Drug Naive HIV-2 Infected Individuals from Maharashtra, India. , 2019, AIDS research and human retroviruses.
[2] S. Rowland-Jones,et al. Delayed disease progression in HIV‐2: the importance of TRIM5α and the retroviral capsid , 2019, Clinical and experimental immunology.
[3] J. Ananworanich,et al. Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test , 2019, Journal of Clinical Microbiology.
[4] R. Serrão,et al. Human Immunodeficiency Virus (HIV) 2 Superinfection in a Patient Receiving Antiretroviral Therapy With Longstanding HIV-1 Viral Load Suppression , 2019, Open forum infectious diseases.
[5] L. Styer,et al. Drug resistance mutations and viral load in human immunodeficiency virus type 2 and dual HIV-1/HIV-2 infected patients in Ghana , 2019, Medicine.
[6] G. Gottlieb,et al. 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. , 2018, The lancet. HIV.
[7] C. Wejse,et al. The influence of human leukocyte antigen-types on disease progression among HIV-2 infected patients in Guinea-Bissau , 2018, AIDS.
[8] J. Mendieta,et al. Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway , 2017, The Journal of Biological Chemistry.
[9] G. Gottlieb,et al. Detection and differentiation of HIV-2 using the point-of-care Alere q HIV-1/2 Detect nucleic acid test. , 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[10] Shaowu Tang,et al. Correct Use of Percent Coefficient of Variation (%CV) Formula for Log-Transformed Data , 2017 .
[11] C. Morrison,et al. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study , 2017, The Journal of antimicrobial chemotherapy.
[12] C. Rouzioux,et al. New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification , 2017, Journal of Clinical Microbiology.
[13] V. Soriano,et al. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response , 2017, The Journal of antimicrobial chemotherapy.
[14] V. Soriano,et al. HIV type 2 epidemic in Spain: challenges and missing opportunities , 2017, AIDS.
[15] C. Nkoke,et al. UNAIDS 90–90–90 targets to end the AIDS epidemic by 2020 are not realistic: comment on “Can the UNAIDS 90–90–90 target be achieved? A systematic analysis of national HIV treatment cascades” , 2017, BMJ Global Health.
[16] C. Charpentier,et al. Hiv-2 molecular epidemiology. , 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[17] C. Wejse,et al. High prevalence and excess mortality of late presenters among HIV-1, HIV-2 and HIV-1/2 dually infected patients in Guinea-Bissau - a cohort study from West Africa , 2016, The Pan African medical journal.
[18] F. Dabis,et al. Mortality and survival patterns of people living with HIV-2 , 2016, Current opinion in HIV and AIDS.
[19] S. Rowland-Jones,et al. Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2–Infected Controllers , 2016, The Journal of Immunology.
[20] Guixia Yu,et al. Two human immunodeficiency virus Type 2 cases in US blood donors including serologic, molecular, and genomic characterization of an epidemiologically unusual case , 2016, Transfusion.
[21] N. Hasegawa,et al. Qualitative Real-Time PCR Assay for HIV-1 and HIV-2 RNA. , 2016, Japanese journal of infectious diseases.
[22] J. Sterne,et al. Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort , 2016, Journal of the International AIDS Society.
[23] C. Charpentier,et al. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] C. Charpentier,et al. Genotypic resistance profiles of HIV-2-treated patients in West Africa , 2014, AIDS.
[25] V. Jansen,et al. Protection Versus Pathology in Aviremic and High Viral Load HIV-2 Infection—The Pivotal Role of Immune Activation and T-cell Kinetics , 2014, The Journal of infectious diseases.
[26] Y. Liu,et al. Discrepant Amplification Results during the Development of an Assay Leads to Reclassification of Two AIDS Reagent Repository HIV-2 Isolates as HIV-1 , 2014, PloS one.
[27] P. Goubau,et al. Validation of an ultrasensitive digital droplet PCR assay for HIV-2 plasma RNA quantification , 2014, Journal of the International AIDS Society.
[28] M. Parker,et al. Validation and clinical use of a sensitive HIV-2 viral load assay that uses a whole virus internal control. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[29] G. Gottlieb,et al. Complex Patterns of Protease Inhibitor Resistance among Antiretroviral Treatment-Experienced HIV-2 Patients from Senegal: Implications for Second-Line Therapy , 2013, Antimicrobial Agents and Chemotherapy.
[30] G. Gottlieb,et al. Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[31] F. Månsson,et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. , 2012, The New England journal of medicine.
[32] A. Heath,et al. Preparation and evaluation of the 1st international standard for the quantitation of HIV-2 RNA in plasma. , 2011, Journal of virological methods.
[33] R. Charrel,et al. RNA and DNA Bacteriophages as Molecular Diagnosis Controls in Clinical Virology: A Comprehensive Study of More than 45,000 Routine PCR Tests , 2011, PloS one.
[34] Eileen M. Burd,et al. Validation of Laboratory-Developed Molecular Assays for Infectious Diseases , 2010, Clinical Microbiology Reviews.
[35] E. Sanders-Buell,et al. Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines , 2005, Journal of Virology.
[36] S. Popper,et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. , 1999, The Journal of infectious diseases.
[37] J. Mascola,et al. Development of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 and Performance of an Improved AMPLICOR HIV-1 MONITOR Test with Isolates of Diverse Subtypes , 1999, Journal of Clinical Microbiology.
[38] G. Gottlieb,et al. Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm. , 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[39] HIV-2 Infection Surveillance--United States, 1987-2009. , 2011, MMWR. Morbidity and mortality weekly report.